| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Mouse |
| Target | prostatic carcinoma cells |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Identifiers | |
| CAS number | 151763-64-3 (capromab) 148805-91-8 (pendetide) |
| ATC code | V09IB04 |
| ChEMBL | CHEMBL1201579 |
| Chemical data | |
| Formula | ? |
| (what is this?) (verify) |
|
Indium (111In) capromab pendetide (trade name Prostascint) is used to image the extent of prostate cancer.[1] Capromab is a mouse monoclonal antibody which recognizes prostate specific membrane antigen (PSMA) from prostate cancer cells and normal prostate tissue. It is linked to pendetide, a derivative of DTPA.[2] Pendetide acts as a chelating agent for the radionuclide indium-111. Following an intravenous injection of Prostascint, imaging is performed using single photon emission computed tomography (SPECT).[1]
Early trials with yttrium (90Y) capromab pendetide were also conducted.[3]
|
||||||||||||||||||||||||||||||||